92 results about "Medications therapy" patented technology

A method, apparatus, and system for treating patients suffering from movement disorders having the ability to determine one or more biomarkers indicative of a disease state. In some embodiments, the biomarker may be used as a closed-loop feedback signal to control the delivery of therapy (such as electrical stimulation or drug therapy), and which may also be used as an indication of therapy effectiveness. One embodiment uses electrodes placed in the brain to measure EEG or local field potential (LFP) signals, from which the one or more biomarkers may be determined.

An apparatus, system and method of programming a medical therapy in a medical device are provided. Generally, the medical device 10 has a controller 12, a memory 14, a processor 16 and an input device 18. The memory 14 is preloaded with at least one of a plurality of patient profiles and condition profiles. The memory 14 is further preloaded with an associated medication therapy for a plurality of the profiles. The input device 18 receives profile data 90, 91 comprising at least one of a patient profile data and a condition profile data for a specific patient, and the processor 16 processes the received profile data 100 and provides as output one of the preloaded medication therapies based on the processed profile data 102.

Systems and methods provide for gathering of patient related data during non-sleep periods and modulating a therapy delivered to the patient during sleep using the gathered data. Data associated with a patient is gathered while the patient is awake. A therapy delivered to the patient during patient sleep is adjusted using the acquired data. The therapy delivered to the patient may include one or more of a respiratory therapy, such as a positive airway pressure (xPAP) therapy, a sleep disordered breathing therapy, a cardiac rhythm management therapy, such as a cardiac overdrive pacing therapy, a medication therapy, or a drug delivery therapy. The therapy delivered to the patient may be optimized using the acquired data.

A system and method for monitoring and delivering medication to a patient includes a controller that has a control algorithm and a closed loop control that monitors the control algorithm. A sensor is in communication with the controller and monitors a medical condition. A rule base application in the controller receives data from the sensor and the closed loop control and compares the data to predetermined medical information to determine the risk of automation of therapy to the patient. The controller then provides a predetermined risk threshold where below the predetermined risk threshold automated closed loop medication therapy is provided. If the predetermined risk threshold is met or exceeded, automated therapy adjustments may not occur and user / clinician intervention is requested.

An automated small items dispensing apparatus is disclosed. In a preferred embodiment, the invention includes a networked, programmable, automatic medication items dispensing apparatus for use by individual patients who are enrolled in a medication protocol or medication therapy regimen. The device is located separate from the patient's health care provider's facility, such as in the patient's home.

A “medication communicator” chart is used as a teaching tool to educate patients and to schedule events corresponding to a prescribed medication regimen. The “medication communicator” chart includes a scheduling graph having the shape of a 12-hour or 24-hour analog clock. The scheduling graph is divided into regions corresponding to each hour of a day for scheduling event information. Fields, on the “medication communicator” chart, are receptive to labels communicating information corresponding to numerous medications in the medication regimen. Timing indicators may be applied to the regions of the scheduling graph to indicate consumption or application times of each of the medications.

System and method for the cost-effective use of medications, comprising dynamically adjusting the patient cost for a plurality of possible medication treatment therapies according to the cost-effectiveness of each possible medication therapy based on known patient attributes, and providing a physician with the dynamically determined patient cost of at least one of the possible medication treatment therapies.

A ministering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Celiac Sprue and / or dermatitis herpetiformis arc treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the ability to bind tightly to HLA molecules; (ii) retain the protcolytic stability of these peptides; but (iii) are unable to activate disease-specific T cells.

The invention is directed to a method for determining the total amount of liquid medicament containing an active drug substance to be aerosolized and inhaled by a patient in order to deliver a pharmaceutically effective amount (“PEA”) of said drug to the respiratory tract of said patient comprising: A) aerosolizing a measured amount of said medicament liquid containing a known amount of drug (“Aerosolized Dose”) using an aerosolization means connected to said patient via an inhalation tube and an exhalation tube; wherein said exhalation tube contains a filter means and wherein said Aerosolized Dose is less than said PEA of said drug; B) administering said aerosol to the respiratory tract of said patient via said inhalation tube; C) allowing the patient to exhale through said exhalation tube containing said filter wherein any exhaled drug is trapped on said filter; D) measuring the reflectance of the color on the filter media contained in said exhalation filter using a reflectance spectrophotometer to determine the amount of drug on said exhalation filter (“Exhaled Dose”); E) determining the actual dose delivered to said patient (“Delivered Dose”) as follows: Aerosolized Dose minus Trapped Dose minus Exhaled Dose=Delivered Dose, where the Trapped Dose is the amount of drug trapped in the inhalation tube; and F) calculating the total amount of liquid medicament to be aerosolized (“Total Aerosolized Dose”) by multiplying the PEA by the result of dividing the Delivered Dose by the Aerosolized Dose; wherein a solution or suspension of the drug is colored when viewed by the human eye or wherein the drug reacts with a reagent on the filter media of said filter means to produce a color.

A system and method for monitoring and delivering medication to a patient. The system includes a controller that has a control algorithm and a closed loop control that monitors the control algorithm. A sensor is in communication with the controller and monitors a medical condition. A rule based application in the controller receives data from the sensor and the closed loop control and compares the data to predetermined medical information to determine the risk of automation of therapy to the patient. A system monitor is also in communication with the controller to monitor system, remote system, and network activity and conditions. The controller then provides a predetermined risk threshold where below the predetermined risk threshold automated closed loop medication therapy is provided. If the predetermined risk threshold is met or exceeded, automated therapy adjustments may not occur and user / clinician intervention is requested.

A method for population and patient-specific medication therapy review using a computer particularly adapted for a medication therapy management or health care delivery organization is provided, wherein the method includes at least the steps of: collecting patient claims data; reviewing the patient claims data for accuracy and data integrity; identifying particular characteristics sought within the patient claims data; organizing and structuring the patient claims data; establishing a set of clinical rules; transforming the set of clinical rules established into a computer language, and entering the transformed clinical rules into an electronic database; and analyzing the patient claims data by applying the clinical rules using a computer particularly adapted for a medication therapy management or health care delivery organization, thereby producing an analytical result. In further embodiments, the analytic results are used to evaluate the need for patient-level medication therapy review and, optionally, to actually conduct a patient-level medication therapy review based on the review of the analytic results.

Genetic markers in the HLA-DQB1 gene associated with adverse hematological response to drug therapy are disclosed. Compositions and methods for detecting and using these HLA-DQB1 markers in a variety of clinical applications are disclosed. Such applications include methods for testing an individual for susceptibility for an adverse hematological response, methods of selecting the appropriate drug therapy for patients based on the presence or absence of a HLA-DQB1 marker, and products comprising a drug with hematological toxicity that are approved for treating patients lacking a genetic marker.

The present invention relates to a structure having a nanoantenna, a method for manufacturing same, a drug delivery body having the same, a thermotherapy complex, a drug therapy device, and a thermotherapy device. The structure of the present invention has a nanoantenna pattern formed on the outer surface of a porous micro-container, thereby enabling wireless control from the outside, and when the structure is used as a drug delivery system and a thermotherapy complex, drug therapy and thermotherapy can be carried out at a desired application region inside a living body at a desired time. Also, the structure of the present invention enables transmission and reception of a wireless signal with an external controller through the nanoantenna, thereby enabling the detection of a signal inside the living body and the transmission of the signal to the external controller, and the discharge of a drug or nanowires according to a response signal transmitted from the external controller.

Genetic markers in the HLA-C gene associated with adverse hematological response to drug therapy are disclosed. Compositions and methods for detecting and using these HLA-C markers in a variety of clinical applications are disclosed. Such applications include methods for testing an individual for susceptibility for an adverse hematological response, methods of selecting the appropriate drug therapy for patients based on the presence or absence of a HLA-C marker, and products comprising a drug with hematological toxicity that are approved for treating patients lacking a genetic marker.

This invention provides methods and compositions for screening of microRNA capable of modulating gene expression in the apoptotic pathway in the presence of HSP90 inhibitor. The use of miRNA for enhancing the activity of therapeutic agents not limited to HSP90 inhibitor is also disclosed. The diagnostic use of miRNA for predicting response to therapy not limited to therapeutic agents is also disclosed. A method for the identification and therapeutic application of small molecules which are modulators of these nucleic acids are also included in this application

The invention relates to an application of histone H2B based mono-ubiquitination for detecting homologous recombination repair defects, in particular to a kit for detecting homologous recombination repair defects based on histone H2B mono-ubiquitination level and an application thereof. The application is to detect the defect of homologous recombination repair by detecting the histone H2B mono-ubiquitination level, and the result contributes to distinguishing the progress of related diseases and the responsiveness of homologous recombination targeted drug therapy such as PARP inhibitor and thelike, including but not limited to liver tissues or liver cancer with hepatitis B virus, and various tumors with homologous recombination gene mutation, expression and splicing body abnormality.

Disclosed is a medication therapy system for curing nephropathy in a rehabilitation mode through targeted guiding of Chinese herbal medicinal ingredients into a renal region. The system comprises a renal region Chinese herbal medicinal ingredient leading-in instrument, a thermal therapy belt and a drug administration device, the renal region Chinese herbal medicinal ingredient leading-in instrument comprises a controller which can generate an electronic biological wave so as to comprehensively treat human body diseased tissue, the controller can reset output intensity and magnetic thermal therapy temperature to zero automatically and in advance when the renal region Chinese herbal medicinal ingredient leading-in instrument is powered on and control treatment time, treatment mode, output intensity, output frequency, magnetic thermal therapy starting and stopping and magnetic thermal therapy temperature adjustment, when the treatment timing is finished, the instrument is automatically stopped, the thermal therapy belt holds the drug administration device and encircles on the waist of a patient, a drug guiding electrode plate of the thermal therapy belt is communicated with the renal region Chinese herbal medicinal ingredient leading-in instrument through a guide line, and the drug administration device contains the Chinese herbal medicine. By means of the medication therapy system for curing the nephropathy in the rehabilitation mode through targeted guiding of Chinese herbal medicinal ingredients into the renal region, suffering of the patient caused by oral drugs is avoided, the therapeutic effect is good, the treatment cost is low, and a safe, simple, convenient, rapid and painless treatment method is achieved.

The present invention provides a method and devices for the treatment of hemorrhoids. The method involves the combined delivery of cryotherapy and medication therapy. The devices described provide cryotherapy for immediate relief of pain, itching, reduction of swelling, reduction of existing bleeding, shrinkage of hemorrhoidal tissue, and promotes healing of affective tissues. Subsequent medication release from these devices provides sustained healing and protracted relief of symptoms. The devices may be disposable and may be used externally or internally, and may include an invasive or non-invasive applicator.

The invention provides an ultrasonic medication therapy comb to solve the problem that the existing medication comb has the function of medication only. The ultrasonic medication therapy comb comprises teeth, an inner shell, an outer shell, a control panel, an ultrasonic head and a medication hole. The teeth of metal are arranged at one end of the bottom of the outer shell; the teeth of plastic are arranged at the other end of the bottom of the outer shell. The ultrasonic head is disposed between the teeth of metal and the teeth of plastic. The control panel is arranged on the upper portion of the outer shell. The medication hole is arranged in the back of the outer shell. The inner shell is arranged within the outer shell. A drug passage is arranged in the inner shell; one end of the drug passage is connected with the medication hole; the other end of the drug passage is connected with the teeth of metal; the teeth of metal are hollow; a ball is disposed within each tooth of metal. The ultrasonic medication therapy comb is a novel medical, health-care, rehabilitation and physiotherapy instrument which is simple in structure and which integrates the traditional medicine and the modern high-tech; a novel therapy method is provided for the treatment of head skin diseases. The ultrasonic medication therapy comb has the advantages that the treatment range is widened, and treatment effect is improved.